Market Overview

Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL in Bladder, Lung, Breast and HPV-Associated Cancers

Share:

Lion Biotechnologies
(Nasdaq: LBIO), a biotechnology company that is developing novel cancer
immunotherapies based on tumor-infiltrating lymphocytes (TIL), today
announced that it has obtained an exclusive, worldwide license from the
National Institutes of Health (NIH) to develop and commercialize TIL therapy
in four additional tumor indications. Under the agreement, the NIH has
granted Lion exclusive rights to certain patents to develop TIL in the
treatment of bladder, lung, breast and HPV-associated cancers, including
cervical and head and neck.
The agreement was executed as an amendment to Lion's existing exclusive
licensing agreement with the NIH for the development and commercialization
of TIL in the treatment of metastatic melanoma. As consideration for the
license, Lion will make an upfront payment to the NIH, payable half within
60 days of closing and the balance a year later. Additional milestone
payments, which will vary according to indication, will be based on
completion of specific clinical, regulatory and commercial milestones. The
agreement also calls for royalties to be payable to the NIH based on
revenues, and certain additional payments under different sublicense
scenarios.
"In addition to the efficacy previously reported in melanoma, we believe
that TIL therapy has the potential to demonstrate significant clinical
benefit in the treatment of many solid tumors," said Elma Hawkins, PhD,
Lion's president and chief executive officer. "Having exclusivity in these
additional indications will enable us to further our development efforts in
other tumor types, with the goal of providing a new treatment option for
patients."

 

Related Articles (LBIO)

View Comments and Join the Discussion!

Posted-In: News Contracts Press Releases